Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab govitecan vs physician's choice in HR+/HER2- metastatic breast cancer
NCT05840211Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- May 2023
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 28
01
Overview
A Phase 3 trial of sacituzumab govitecan in breast cancer, sponsored by Gilead Sciences. Started May 2023; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05840211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05840211.